Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Acurx Pharmaceuticals ( (ACXP) ) has provided an update.
On July 17, 2025, Acurx Pharmaceuticals held its annual meeting where 74.38% of its outstanding shares were represented. During the meeting, stockholders elected Class I directors to serve until 2028 and ratified the appointment of CohnReznick LLP as the independent auditors for the fiscal year ending December 31, 2025.
The most recent analyst rating on (ACXP) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Acurx Pharmaceuticals stock, see the ACXP Stock Forecast page.
Spark’s Take on ACXP Stock
According to Spark, TipRanks’ AI Analyst, ACXP is a Underperform.
Acurx Pharmaceuticals’ score reflects the challenges of an early-stage biotech, including lack of revenue and ongoing losses, balanced by strong potential in clinical advancements and regulatory support. Technical indicators suggest weak momentum, and valuation is hindered by financial fundamentals.
To see Spark’s full report on ACXP stock, click here.
More about Acurx Pharmaceuticals
Average Trading Volume: 6,424,739
Technical Sentiment Signal: Sell
Current Market Cap: $12.75M
For a thorough assessment of ACXP stock, go to TipRanks’ Stock Analysis page.